Viridian Therapeutics, Inc./DE
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $-61.9M | $22.1M |
| FY2017 | $10.0M | $38.5M | $47.4M |
| FY2018 | $10.0M | $51.3M | $32.6M |
| FY2019 | $7.7M | $15.8M | $24.8M |
| FY2020 | — | $120.0M | $45.9M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $-61.9M | $22.1M |
| FY2017 | $10.0M | $38.5M | $47.4M |
| FY2018 | $10.0M | $51.3M | $32.6M |
| FY2019 | $7.7M | $15.8M | $24.8M |
| FY2020 | — | $120.0M | $45.9M |